While molecular testing is now routine in cancer and women's health, for other disease areas, the technology may be overkill, Sundin said.
Centralized and point-of-care division sales contributed most to the revenue growth, and were spurred on by a 13 percent lift in immunodiagnostics revenues.
Myriad said it will submit a supplementary premarket approval application for its BRACAnalysis CDx, which the FDA originally approved in 2014.
The company, which beat Wall Street expectations on the top and bottom lines, said completed Cologuard test volume rose 150 percent over Q1 2016.
The company's second quarter revenue growth was driven in part by strong sales from its life science segment.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.